BCIQ Profiles

Company Profile Report
0707 QT
BioCentury & Getty Images

Product Development

July 7 Quick Takes: Moderna launches flu trial of mRNA vaccine; plus Quidel recall, NIH, WHO, Boehringer-Lilly, Novartis and more

Jul 8, 2021 | 12:16 AM GMT

Moderna Inc. (NASDAQ:MRNA) dosed the first participants in a Phase I/II trial of quadrivalent seasonal mRNA influenza vaccine mRNA-1010 that will help determine whether the manufacturing and efficacy benefits of mRNA vaccines for COVID-19 translate to the flu. The dose-ranging study will enroll about 180 healthy adult participants and

Read the full 798 word article

How to gain access

Continue reading with a
two-week free trial.